The Phase IIb POWER 1 and 2 trials compared the efficacy and safety of darunavir plus low-dose ritonavir (darunavir/ritonavir) with currently available PIs in highly treatment-experienced patients ...
The third pivotal study in treatment-naive patients compared dolutegravir to the DHHS guideline recommended boosted protease inhibitor darunavir/ritonavir. The FLAMINGO study is a 96-week ...
Potentiated by CYP3A4 inhibitors (eg, ritonavir, ritonavir/darunavir, ritonavir/fosamprenavir); adjust ketoconazole dose as needed. Separate dosing of acid neutralizing drugs (eg, aluminum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback